Search research articles
Contact Us
Filters
Showing results (61-70 of 186) with videos related to
Page
of 19
Sort By:
Pediatric Blood & Cancer
|
April 21, 2021
A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515)
Thomas Cash, Elizabeth Fox, Xiaowei Liu, et al.
Journal of the National Cancer Institute
|
May 13, 2010
Pediatric phase I trial design using maximum target inhibition as the primary endpoint
Holly Meany, Frank M Balis, Alberta Aikin, et al.
Cancer
|
September 9, 2017
Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials
Wendy B London, Rochelle Bagatell, Brenda J Weigel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 24, 2020
Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting
Navid Hafez, Hope S Rugo, Margaret A Tempero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 7, 2018
New Agents, Emerging Late Effects, and the Development of Precision Survivorship
Eric J Chow, Zoltan Antal, Louis S Constine, et al.
Pediatric Blood & Cancer
|
June 26, 2014
Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors
Robin E Norris, Suzanne Shusterman, Lia Gore, et al.
Stroke
|
March 11, 2021
Care of the Patient With Acute Ischemic Stroke (Endovascular/Intensive Care Unit-Postinterventional Therapy): Update to 2009 Comprehensive Nursing Care Scientific Statement: A Scientific Statement From the American Heart Association
Mary L Rodgers, Elizabeth Fox, Tamer Abdelhak, et al.
Cerebral Cortex (New York, N.Y. : 1991)
|
December 24, 2014
Prenatal Exposure to Autism-Specific Maternal Autoantibodies Alters Proliferation of Cortical Neural Precursor Cells, Enlarges Brain, and Increases Neuronal Size in Adult Animals
Verónica Martínez-Cerdeño, Jasmin Camacho, Elizabeth Fox, et al.
Pediatric Blood & Cancer
|
March 12, 2022
Neuroblastoma and cutaneous angiosarcoma in a child with PTEN hamartoma tumor syndrome
Michael S Leibowitz, Kristin Zelley, Denise Adams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 14, 2022
Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric <i>BRAF</i> V600-Mutant Low-Grade Glioma
Eric Bouffet, Birgit Geoerger, Christopher Moertel, et al.
Page
of 19
Search research articles
Search
Showing results (61-70 of 186) with videos related to
Sort By:
Page
of 19
Pediatric Blood & Cancer
|
April 21, 2021
A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515)
Thomas Cash, Elizabeth Fox, Xiaowei Liu, et al.
Journal of the National Cancer Institute
|
May 13, 2010
Pediatric phase I trial design using maximum target inhibition as the primary endpoint
Holly Meany, Frank M Balis, Alberta Aikin, et al.
Cancer
|
September 9, 2017
Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials
Wendy B London, Rochelle Bagatell, Brenda J Weigel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 24, 2020
Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting
Navid Hafez, Hope S Rugo, Margaret A Tempero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 7, 2018
New Agents, Emerging Late Effects, and the Development of Precision Survivorship
Eric J Chow, Zoltan Antal, Louis S Constine, et al.
Pediatric Blood & Cancer
|
June 26, 2014
Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors
Robin E Norris, Suzanne Shusterman, Lia Gore, et al.
Stroke
|
March 11, 2021
Care of the Patient With Acute Ischemic Stroke (Endovascular/Intensive Care Unit-Postinterventional Therapy): Update to 2009 Comprehensive Nursing Care Scientific Statement: A Scientific Statement From the American Heart Association
Mary L Rodgers, Elizabeth Fox, Tamer Abdelhak, et al.
Cerebral Cortex (New York, N.Y. : 1991)
|
December 24, 2014
Prenatal Exposure to Autism-Specific Maternal Autoantibodies Alters Proliferation of Cortical Neural Precursor Cells, Enlarges Brain, and Increases Neuronal Size in Adult Animals
Verónica Martínez-Cerdeño, Jasmin Camacho, Elizabeth Fox, et al.
Pediatric Blood & Cancer
|
March 12, 2022
Neuroblastoma and cutaneous angiosarcoma in a child with PTEN hamartoma tumor syndrome
Michael S Leibowitz, Kristin Zelley, Denise Adams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 14, 2022
Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric <i>BRAF</i> V600-Mutant Low-Grade Glioma
Eric Bouffet, Birgit Geoerger, Christopher Moertel, et al.
Page
of 19